Option chain shows key data for Lonza Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lonza Group.

Lonza Group (OTC:LZAGF) Stock, Option Chain

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

BZ_briefs

Analyst Color

News

Health Care

Analyst Ratings

General

LZAGF

LZAGY

Lonza unveils its &#34;One Lonza&#34; strategy, highlighting a new structure to streamline operations, strengthen CDMO leadership, and project 20% CER sales growth in 2025.

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development

Roche

Biotech

RHHBY

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to boost sales growth. Closing anticipated by H2 2024.

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche&#39;s US Facility Acquisition For $1.2B

GLPG

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

Lonza Group Ltd

Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript

Medpace: Clear Winner If China Blockade Succeeds

Artisan International Fund Q2 2024 Commentary

Lonza Group AG 2024 Q2 - Results - Earnings Call Presentation

Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript

Innospec Navigating Turbulent End-Markets And Specialty Chemical De-Rating Relatively Well

Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules

Baron Emerging Markets Fund Q3 2024 Shareholder Letter

Thornburg International Growth Fund Q3 2024 Commentary

Vertex reports positive long-term data for Casgevy

AMZN

APAM

ARGX

ASML

ASMLF

ASND

AZNCF

BABA

BABAF

BAIDF

BAMXF

BCAP

BDRFF

BDRFY

BIDU

BMWYY

BROE

BYMOF

CATL

CIADF

CIADY

CLZNF

CLZNY

CRSP

CTLT

DISPF

DSCSY

DSFIY

DSMFF

EVKIF

EVKIY

FUJIF

FUJIY

HOCPF

HOCPY

HXSCF

ICLR

INPOF

INPOY

IOSP

KYCCF

LZRFY

MBGAF

MBGYY

MBLY

MEDP

MELI

MIELF

MIELY

MLSPF

MPNGF

MPNGY

NONOF

NRILY

NSRGF

NSRGY

NURAF

NVDA

RSNHF

RYAAY

RYAOF

SNYNF

SSNLF

STLA

SVNDF

SVNDY

TCEHY

TCTZF

TSLA

TSMWF

UCBJF

UCBJY

VRTX

WEGZY

WMMVF

WMMVY

WXIBF

WXXWY

Small Cap

Press Releases

NeuroSense Announces First Quarter 2024 Business Update

NRSN

Lonza Group

Comments

Lonza Group

Lonza Group (LZAGF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga